G&S Capital LLC Raises Stock Holdings in Boston Scientific Co. (NYSE:BSX)

G&S Capital LLC boosted its stake in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 99.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 27,242 shares of the medical equipment provider's stock after acquiring an additional 13,572 shares during the quarter. G&S Capital LLC's holdings in Boston Scientific were worth $2,433,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA raised its stake in Boston Scientific by 9.7% in the third quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 1,352 shares of the medical equipment provider's stock valued at $115,000 after purchasing an additional 119 shares in the last quarter. Adero Partners LLC lifted its stake in Boston Scientific by 3.3% during the fourth quarter. Adero Partners LLC now owns 3,737 shares of the medical equipment provider's stock worth $334,000 after purchasing an additional 120 shares during the last quarter. Grove Bank & Trust boosted its holdings in shares of Boston Scientific by 4.4% in the 4th quarter. Grove Bank & Trust now owns 2,923 shares of the medical equipment provider's stock valued at $261,000 after purchasing an additional 122 shares in the last quarter. PFG Investments LLC increased its stake in shares of Boston Scientific by 1.6% in the 4th quarter. PFG Investments LLC now owns 8,113 shares of the medical equipment provider's stock valued at $725,000 after purchasing an additional 125 shares during the last quarter. Finally, Stonegate Investment Group LLC raised its holdings in shares of Boston Scientific by 1.6% during the 4th quarter. Stonegate Investment Group LLC now owns 7,827 shares of the medical equipment provider's stock worth $699,000 after buying an additional 126 shares in the last quarter. 89.07% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms recently weighed in on BSX. Mizuho raised their price objective on Boston Scientific from $100.00 to $110.00 and gave the company an "outperform" rating in a research note on Thursday, October 24th. Stifel Nicolaus increased their price target on Boston Scientific from $100.00 to $115.00 and gave the company a "buy" rating in a research note on Thursday, February 6th. Deutsche Bank Aktiengesellschaft upgraded Boston Scientific from a "hold" rating to a "buy" rating and set a $108.00 price objective on the stock in a research report on Friday, January 10th. Citigroup increased their target price on Boston Scientific from $107.00 to $122.00 and gave the company a "buy" rating in a research report on Thursday, February 6th. Finally, Barclays boosted their price target on Boston Scientific from $111.00 to $118.00 and gave the stock an "overweight" rating in a report on Monday, February 10th. One equities research analyst has rated the stock with a hold rating, twenty-two have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Boston Scientific currently has an average rating of "Buy" and an average target price of $107.39.

Insider Buying and Selling

In other news, Director Edward J. Ludwig sold 4,877 shares of the business's stock in a transaction dated Thursday, November 21st. The shares were sold at an average price of $91.63, for a total transaction of $446,879.51. Following the completion of the sale, the director now directly owns 39,398 shares of the company's stock, valued at $3,610,038.74. The trade was a 11.02 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Arthur C. Butcher sold 14,010 shares of the company's stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $89.27, for a total transaction of $1,250,672.70. Following the completion of the sale, the executive vice president now owns 978 shares in the company, valued at $87,306.06. This represents a 93.47 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 87,326 shares of company stock valued at $8,673,948 over the last ninety days. 0.50% of the stock is owned by corporate insiders.

Boston Scientific Trading Up 0.1 %

Shares of BSX stock traded up $0.06 during mid-day trading on Monday, hitting $106.20. The company's stock had a trading volume of 3,966,417 shares, compared to its average volume of 6,179,673. The company has a market cap of $156.51 billion, a PE ratio of 84.96, a P/E/G ratio of 2.79 and a beta of 0.80. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.02 and a current ratio of 1.48. The company's fifty day simple moving average is $96.44 and its 200-day simple moving average is $88.39. Boston Scientific Co. has a 52 week low of $65.33 and a 52 week high of $107.17.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, topping analysts' consensus estimates of $0.65 by $0.05. Boston Scientific had a return on equity of 18.11% and a net margin of 11.07%. As a group, equities research analysts expect that Boston Scientific Co. will post 2.83 earnings per share for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.